PMID- 32114643
OWN - NLM
STAT- MEDLINE
DCOM- 20200826
LR  - 20210217
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Print)
IS  - 0940-5429 (Linking)
VI  - 57
IP  - 7
DP  - 2020 Jul
TI  - Baseline SD-OCT characteristics of diabetic macular oedema patterns can predict 
      morphological features and timing of recurrence in patients treated with 
      dexamethasone intravitreal implants.
PG  - 867-874
LID - 10.1007/s00592-020-01504-w [doi]
AB  - AIMS: To evaluate the timing and spectral-domain optical coherence tomography 
      (SD-OCT) features of diabetic macular oedema (DME) recurrence according to 
      baseline OCT patterns in patients treated with dexamethasone implant (DEX-I). 
      METHODS: This is a retrospective observational study (72 eyes/65 patients). 
      Best-corrected visual acuity, timing of DME recurrence, and SD-OCT pattern 
      [intraretinal cysts (IRC), IRC plus subretinal fluid (mixed), external limiting 
      membrane (ELM), ellipsoid (IS/OS) layer integrity] were assessed at baseline and 
      monthly until first DME recurrence. RESULTS: Forty-two (58.3%) and 30 (41.6%) DME 
      eyes had an IRC and mixed DME pattern at baseline, respectively. Twenty-four out 
      of thirty mixed eyes (80%) relapsed without subretinal fluid. At baseline, mixed 
      eyes showed similar changes in ELM and IS/OS (60 and 76.6% of eyes, respectively) 
      versus IRC eyes (42.8 and 80.9% of eyes). After DME recurrence, more mixed eyes 
      at baseline showed ELM and IS/OS changes (63.3 and 86.6%) than IRC eyes (50 and 
      76.2%). 33.3% of mixed eyes had DME recurrence at >/= 6 months from first DEX-I 
      implant versus 19% of IRC eyes. CONCLUSIONS: Mixed DME eyes were treated with 
      DEX-I relapse later and more frequently without subretinal fluid than IRC eyes. 
      SD-OCT characteristics of different DME patterns at baseline can predict 
      morphological features and timing of DME recurrence.
FAU - Eandi, Chiara M
AU  - Eandi CM
AUID- ORCID: 0000-0003-3656-1689
AD  - Department of Surgical Sciences, University of Torino, C. Dogliotti 14, 10126, 
      Turin, Italy. chiara.eandi@unito.it.
AD  - Department of Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, 
      Fondation Asile des aveugles, Lausanne, Switzerland. chiara.eandi@unito.it.
AD  - Department of Ophthalmology, Fondation Ophtalmologique A. De Rothschild, Paris, 
      France. chiara.eandi@unito.it.
FAU - De Geronimo, Daniele
AU  - De Geronimo D
AD  - IRCCS - Fondazione Bietti, Rome, Italy.
FAU - Giannini, Daniela
AU  - Giannini D
AD  - IRCCS - Fondazione Bietti, Rome, Italy.
FAU - Polito, Maria Sole
AU  - Polito MS
AD  - Department of Surgical Sciences, University of Torino, C. Dogliotti 14, 10126, 
      Turin, Italy.
FAU - Tosi, Gian Marco
AU  - Tosi GM
AD  - Ophthalmology Unit, Department of Medicine, Surgery and Neuroscience, University 
      of Siena, Siena, Italy.
FAU - Neri, Giovanni
AU  - Neri G
AD  - Ophthalmology Unit, Department of Medicine, Surgery and Neuroscience, University 
      of Siena, Siena, Italy.
FAU - Le Mer, Yannick
AU  - Le Mer Y
AD  - Department of Ophthalmology, Fondation Ophtalmologique A. De Rothschild, Paris, 
      France.
FAU - Varano, Monica
AU  - Varano M
AD  - IRCCS - Fondazione Bietti, Rome, Italy.
FAU - Parravano, Mariacristina
AU  - Parravano M
AD  - IRCCS - Fondazione Bietti, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200229
PL  - Germany
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
RN  - 0 (Drug Implants)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Aged
MH  - Dexamethasone/*administration & dosage
MH  - Diabetic Retinopathy/*diagnosis/*drug therapy/pathology
MH  - Drug Implants/administration & dosage
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/*diagnosis/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Organ Size/drug effects
MH  - Prognosis
MH  - Recurrence
MH  - Retina/diagnostic imaging/drug effects/pathology/physiopathology
MH  - Retrospective Studies
MH  - Time Factors
MH  - Tomography, Optical Coherence/*methods
MH  - Treatment Outcome
MH  - Visual Acuity/drug effects
PMC - PMC7311372
OTO - NOTNLM
OT  - Baseline characteristics
OT  - Dexamethasone implant (DEX-I)
OT  - Diabetic macular oedema
OT  - Intravitreal treatment
OT  - Recurrence
OT  - Spectral-domain optical coherence tomography
COIS- MP reports personal fees from Allergan, Bayer, Novartis, outside of the submitted 
      work. YLM reports personal fees from Allergan and Novartis, outside of the 
      submitted work. The other authors have nothing to disclose.
EDAT- 2020/03/03 06:00
MHDA- 2020/08/28 06:00
PMCR- 2020/02/29
CRDT- 2020/03/02 06:00
PHST- 2020/01/16 00:00 [received]
PHST- 2020/02/11 00:00 [accepted]
PHST- 2020/03/03 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/03/02 06:00 [entrez]
PHST- 2020/02/29 00:00 [pmc-release]
AID - 10.1007/s00592-020-01504-w [pii]
AID - 1504 [pii]
AID - 10.1007/s00592-020-01504-w [doi]
PST - ppublish
SO  - Acta Diabetol. 2020 Jul;57(7):867-874. doi: 10.1007/s00592-020-01504-w. Epub 2020 
      Feb 29.